We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
Coronavirus continues to spread across the UK, and around the entire world. Scientists have been working hard to find an effective vaccine to protect against the deadly symptoms of COVID-19. Experts at Pfizer and BioNTech have announced the positive findings of their latest clinical trials, in what is “a great day for science and humanity”.
There is currently no scientifically proven vaccine to prevent coronavirus infection.
But, there are a number of treatments that may help to reduce the symptoms and risk of death from COVID-19.
Scientists at pharmaceutical companies Pfizer and BioNTech are working on a possible vaccine, and they’re in the final stages of research.
The experts have now revealed that their own COVID-19 vaccine is 90 percent effective in protecting against infection from the deadly virus.
Scientists branded the clinical trial results as “a great day for science and humanity”.
More than 43,000 people were included in the research – all of which were not infected before trials started.
The companies claimed their vaccine was 90 percent effective in patients.
They’ve now applied for emergency approval to use the vaccine by the end of November.
DON’T MISS
Nicola Sturgeon labels new vaccine development as ‘best news’ for UK [NEWS]
Coronavirus poll: Should lockdown be lifted EARLY after PM pressured [POLL]
Boris Johnson speech: What time is PM’s press conference today? [LATEST]
“Today is a great day for science and humanity,” said Pfzier’s chairman and CEO, Dr Albert Bourla.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most.
“With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.
“We could not have come this far without the tremendous commitment of everyone involved.”
Pfizer believes it can produce up to 50 million vaccine doses by the end of the year.
It also expects to make up to 1.3 billion doses in 2021.
The latest coronavirus vaccine update came days after experts at the University of Oxford announced they were assessing the effectiveness of aspirin in protecting against the complications of COVID-19.
Aspirin is commonly used to reduce the risk of blood clots that may be linked to heart attacks, stroke, or pre-eclampsia.
COVID-19 patients are at higher risk of developing blood clots than the general public, the scientists explained.
Therefore, there is a “clear rationale” for treating patients with aspirin.
Scientists with give 150mg of aspirin daily to 2,000 coronavirus patients, and compare the results with a further 2,000 patients that will only receive the current available treatments.
But the results from the aspirin research will take almost a month before analysis starts.
Source: Read Full Article
